Cargando…
Commentary on the MID3 Good Practices Paper
During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory assessment of medicines. In the 2011 EMA – European Federation of Pharma...
Autores principales: | Manolis, Efthymios, Brogren, Jacob, Cole, Susan, Hay, Justin L., Nordmark, Anna, Karlsson, Kristin E., Lentz, Frederike, Benda, Norbert, Wangorsch, Gaby, Pons, Gerard, Zhao, Wei, Gigante, Valeria, Serone, Francesca, Standing, Joseph F., Dokoumetzidis, Aris, Vakkilainen, Juha, van den Heuvel, Michiel, Mangas Sanjuan, Victor, Taminiau, Johannes, Kerwash, Essam, Khan, David, Musuamba, Flora Tshinanu, Skottheim Rusten, Ine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529732/ https://www.ncbi.nlm.nih.gov/pubmed/28653481 http://dx.doi.org/10.1002/psp4.12223 |
Ejemplares similares
-
Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework
por: Skottheim Rusten, Ine, et al.
Publicado: (2021) -
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility
por: Musuamba, Flora T., et al.
Publicado: (2021) -
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014)
por: Musuamba, FT, et al.
Publicado: (2017) -
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
por: Manolis, Efthymios, et al.
Publicado: (2023) -
Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
por: D’Agate, Salvatore, et al.
Publicado: (2020)